KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Current Deferred Revenue: 2020-2025

Historic Current Deferred Revenue for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $21.5 million.

  • AbCellera Biologics' Current Deferred Revenue rose 57.46% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.5 million, marking a year-over-year increase of 57.46%. This contributed to the annual value of $19.2 million for FY2024, which is 29.21% down from last year.
  • Latest data reveals that AbCellera Biologics reported Current Deferred Revenue of $21.5 million as of Q3 2025, which was down 24.65% from $28.6 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Current Deferred Revenue peaked at $41.1 million during Q4 2022, and registered a low of $13.7 million during Q3 2024.
  • Over the past 3 years, AbCellera Biologics' median Current Deferred Revenue value was $27.2 million (recorded in 2023), while the average stood at $25.8 million.
  • As far as peak fluctuations go, AbCellera Biologics' Current Deferred Revenue slumped by 60.36% in 2024, and later spiked by 98.89% in 2025.
  • AbCellera Biologics' Current Deferred Revenue (Quarterly) stood at $35.0 million in 2021, then climbed by 17.66% to $41.1 million in 2022, then tumbled by 33.98% to $27.2 million in 2023, then declined by 29.21% to $19.2 million in 2024, then surged by 57.46% to $21.5 million in 2025.
  • Its last three reported values are $21.5 million in Q3 2025, $28.6 million for Q2 2025, and $32.5 million during Q1 2025.